• 1
    Brodeur G.M., Pizzo P.A., Poplack D.G. (2001) Principles and Practice of Pediatric Oncology. Neuroblastoma, 4th edn. Philadelphia, USA: Lippencott-Raven; p. 895937.
  • 2
    Berthold F. (1990) Biology of Neuroblastoma. In: PochedlyC., editor. Tumor Biology and Therapy. Boca Raton: CRC Press, p. 127.
  • 3
    Ross R.A., Hein A.M., Braca J.A., Spengler B.A., Biedler J.L., Scammel J.G. (2002) Glucocorticoids induce neuroendocrine cell differentiation and increase expression of N-myc in N-type human Neuroblastoma cells. Oncol Res;13:8794.
  • 4
    Ater J.L. (2007) Neuroblastoma. In: KliegmanR.M., BehrmanR.E., JensonH.B., StantonB.M.D., editors. Nelson Textbook of Pediatrics, 18th edn. St. Louis, USA: Saunders Elsvier; chapter 498.
  • 5
    Matthay K.K., Perez C., Seeger R.C., Brodeur G.M., Shimada H., Atkinson J.B., Black C.T., Gerbing R., Haase G.M., Stram D.O., Swift P., Lukens J.N. (1998) Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol;16:12561264.
  • 6
    Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeu G.M., Gerbing R.B., Reynolds C.P. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med;341:11651173.
  • 7
    Perez C.A., Matthay K.K., Atkinson J.B., Seeger R.C., Shimada H., Haase G.M., Stram D.O., Gerbing R.B., Lukens J.N. (2000) Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. J Clin Oncol;18:1826.
  • 8
    Maris J.M., Matthay K.K. (1999) Molecular biology of neuroblastoma. J Clin Oncol;1999:22642279.
  • 9
    Goldsby R.E., Matthay K.K. (2004) NEUROBLASTOMA: evolving therapies for a disease with many faces. Paediatr Drugs;6:107122.
  • 10
    Matthay K.K., Atkinson J.B., Stram D.O., Selch M., Reynolds C.P., Seeger R.C. (1993) Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol;11:22262233.
  • 11
    Swamy N., Chen T.C., Peleg S., Dhawan P., Christakos S., Stewart L.V., Weigel N.L., Mehta R.G., Holick M.F., Ray R. (2004) Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res;10:80188027.
  • 12
    Swamy N., Persons K.S., Chen T.C., Ray R. (2003) 1α,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1 α,25-dihydroxy-vitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells. J Cell Biochem;89:909916.
  • 13
    Lambert J.R., Young C.D., Persons K.S., Ray R. (2007) Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D(3) derivative in prostate cancer cells. Biochem Biophys Res Commun;361:189195.
  • 14
    Lange T.S., Singh R.K., Kim K.K., Zou Y., Kalkunte S.S., Sholler G.L., Swamy N., Brard L. (2007) Anti-proliferative and pro-apoptotic properties of 3-Bromoacetoxy Calcidiol (B3CD) in high-Risk neuroblastoma. Chem Biol Drug Des;70:302310.
  • 15
    Schmidt-Gayk H., Bouillon R., Roth H.J. (1997) Measurement of vitamin D and its metabolites (calcidiol and calcitriol/vitamin D3) and their clinical significance. Scand J Clin Lab Invest Suppl;227:3545.
  • 16
    Cottens S., Sedrani R. (2002) O-alkylated rapamycin derivatives and their use. United States Patent 6440990.
  • 17
    Driedger P.E., Quick J. (1999) Protein kinase C modulators, E. United States Patent 5886017.
  • 18
    Pession A., Tonelli R. (2005) The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets;5:273283.
  • 19
    Lange T.S., Stuckey A.R., Robison K., Kim K.K., Singh R.K., Raker C.A., Brard L. (2009). Effect of a Vitamin D3 derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. Invest New Drugs [epub ahead of print, July 7 2009].
  • 20
    Zhou H.Y., Pon Y.L., Wong A.S. (2007) Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology;148:51955208.
  • 21
    Ho R., Minturn J.E., Hishiki T., Zhao H., Wang Q., Cnaan A., Maris J., Evans A.E., Brodeur G.M. (2005) Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res;65:98689875.
  • 22
    Chiu B., Mirkin B., Madonna M.B. (2006) Mitogenic and apoptotic actions of epidermal growth factor on Neuroblastoma cells are concentration-dependent. J Surg Res;135:209212.
  • 23
    Swamy N., Ray R. (1996) Affinity labeling of rat serum vitamin D binding protein. Arch Biochem Biophys;333:139144.
  • 24
    Warren J.C., Sweet F. (1975) Synthesis and use of affinity labeling steroids for analysis of macromolecular steroid-binding sites. Methods Enzymol;36:374410.
  • 25
    Ross R.A., Spengler B.A., Biedler J.L. (1983) Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst;71:741747.
  • 26
    Hettmer S., McCarter R., Ladisch S., Kaucic K. (2004) Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer;91:389397.
  • 27
    Kumar R. (2002) 1Alpha,25-dihydroxyvitamin D(3) - not just a calciotropic hormone. Nephron;91:576581.
  • 28
    Shapiro G.I., Harper J.W. (1999) Anticancer drug targets: cell-cycle and checkpoint control. J Clin Invest;104:16451653.
  • 29
    Malich G., Markovic B., Winder C. (1997) The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology;124:179192.
  • 30
    DeLuca H.F., Zierold C. (1998) Mechanisms and functions of vitamin D. Nutr Rev;56:410;54–75.
  • 31
    Dusso A.S., Brown A.J. (1998) Mechanism of vitamin D action and its regulation. Am J Kidney Dis;32(S2):1324.
  • 32
    Olick M.F. (2002) Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes;9:8798.
  • 33
    United Sates Environmental Protection Agency (USEPA) report (2005) Bromoacetic acid – Identification, toxicity, use, water pollution potential, ecological toxicity and regulatory information. CAS number 79-08-3.
  • 34
    Brard L., Robison K., Singh R.K., Kim K.K., Lange T.S. (2007) A novel non-hypercalcemic vitamin D derivative in the treatment of ovarian cancer. J Womens Health;16:10981099.
  • 35
    Blain S., Scher H., Cordon-Cardo C., Koff A. (2003) p27 as a target for cancer therapeutics. Cancer Cell;3:111115.
  • 36
    Sandor V., Senderowicz A., Mertins S., Sackett D., Sausville E., Blagosklonny M.V., Bates S.E. (2000) P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer;83:817825.
  • 37
    Matsuo T., Seth P., Thiele C.J. (2001) Increased expression of p27Kip1 arrests neuroblastoma cell growth. Med Pediatr Oncol;36:9799.
  • 38
    McKenzie P.P., Guichard S.M., Middlemas D.S., Ashmun R.A., Danks M.K., Harris L.C. (1999) Wild-Type p53 Can Induce p21 and Apoptosis in Neuroblastoma Cells But the DNA Damage-induced G1 Checkpoint Function Is Attenuated. Clin Cancer Res;5:41994207.
  • 39
    Pearson G., Robinson F., Beers G.T., Xu B.E., Karandikar M., Berman K., Cobb M.H. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev;22:153183.
  • 40
    Birkenkamp K.U., Dokter W.H., Esselink M.T., Jonk L.J., Kruijer W., Vellenga E. (1999) A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation. Leukemia;13:10371045.
  • 41
    Ahmed-Choudhury J., Williams K.T., Young L.S., Adams D.H., Afford S.C. (2006) SCCD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. Cell Signal;18:456468.
  • 42
    Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., Siddik Z.H., Mills G.B., Claret F.X. (2003) Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem;278:1924519256.
  • 43
    Osone S., Hosoi H., Kuwahara Y., Matsumoto Y., Lehara T., Sugimoto T. (2004) Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells. Int J Cancer;112:219224.
  • 44
    Arvidsson Y., Hamazaki T.S., Ichijo H., Funa K. (2001) ASK1 resistant neuroblastoma is deficient in activation of p38 kinase. Cell Death Differ;8:10291037.
  • 45
    Michaelis M., Bliss J., Arnold S.C., Hinsch N., Rothweiler F., Deubzer H.E., Witt O., Langer K., Doerr H.W. I, Wels W.S., Cinatl J. (2008) Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGF-R) and Are Sensitive to Treatment with EGFR-Specific Toxins. Clin Cancer Res;14:65316537.
  • 46
    Rosseler J., Odenthal E., Geoerger A., Gerstenmeyer A., Lagodny J., Niemmeyer C.M., Vassal G. (2009) EGFR Inhibition Using Gefitinib Is Not Active in Neuroblastoma Cell Lines. Anticancer Res;29:13271333.